Trial Profile
Phase II trial of CX 4945 in combination with erlotinib in patients with non-small cell lung cancer.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2011
Price :
$35
*
At a glance
- Drugs Silmitasertib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Jun 2011 New trial record